{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T22:38:45Z","timestamp":1773873525163,"version":"3.50.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"NIHR HSDR","award":["132075"],"award-info":[{"award-number":["132075"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s41669-025-00622-x","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T14:48:48Z","timestamp":1766069328000},"page":"289-304","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Economic Evaluation of NHS England\u2019s Type 2 Diabetes Path to Remission Pilot Scheme: Evidence From Real-World Data and Patient Simulation Modelling"],"prefix":"10.1007","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2559-6483","authenticated-orcid":false,"given":"Adam","family":"Martin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1020-6235","authenticated-orcid":false,"given":"Tayamika","family":"Zabula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6450-5487","authenticated-orcid":false,"given":"Davide","family":"Tebaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7975-374X","authenticated-orcid":false,"given":"Miaoqing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1285-7098","authenticated-orcid":false,"given":"Tamara","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0559-4832","authenticated-orcid":false,"given":"Louisa","family":"Ells","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"issue":"2","key":"622_CR1","doi-asserted-by":"publisher","first-page":"112","DOI":"10.2174\/157339909788166828","volume":"5","author":"MT Schram","year":"2009","unstructured":"Schram MT, Baan CA, Pouwer F. Depression and quality of life in patients with diabetes: a systematic review from the European depression in diabetes (EDID) research consortium. Curr Diabetes Rev. 2009;5(2):112\u20139.","journal-title":"Curr Diabetes Rev"},{"issue":"11","key":"622_CR2","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S2213-8587(22)00252-2","volume":"10","author":"D Tomic","year":"2022","unstructured":"Tomic D, Morton JI, Chen L, Salim A, Gregg EW, Pavkov ME, et al. Lifetime risk, life expectancy, and years of life lost to type 2 diabetes in 23 high-income jurisdictions: a multinational, population-based study. Lancet Diabetes Endocrinol. 2022;10(11):795\u2013803.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"622_CR3","unstructured":"Office for Health Improvement and Disparities. Public health profiles. 2025. https:\/\/www.gov.uk\/government\/organisations\/office-for-health-improvement-and-disparities\/about\/statistics. Accessed 10 Nov 2025."},{"issue":"7","key":"622_CR4","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S2213-8587(24)00161-X","volume":"12","author":"The Lancet D, and Endocrinology","year":"2024","unstructured":"The Lancet D, and Endocrinology. Alarming rise in young-onset type 2 diabetes. Lancet Diabetes Endocrinol. 2024;12(7):433.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"622_CR5","unstructured":"National Institute for Health and Care Excellence (NICE). Overweight and obesity management guidance GID-NG10182. 2024. https:\/\/www.nice.org.uk\/guidance\/ng246. Accessed 10 Nov 2025."},{"issue":"7","key":"622_CR6","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1111\/j.1464-5491.2012.03698.x","volume":"29","author":"N Hex","year":"2012","unstructured":"Hex N, Bartlett C, Wright D, Taylor M, Varley D. Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med. 2012;29(7):855\u201362.","journal-title":"Diabet Med"},{"issue":"8","key":"622_CR7","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s40273-015-0268-9","volume":"33","author":"T Seuring","year":"2015","unstructured":"Seuring T, Archangelidi O, Suhrcke M. The economic costs of type 2 diabetes: a global systematic review. Pharmacoeconomics. 2015;33(8):811\u201331.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"622_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s00125-021-05577-2","volume":"65","author":"C Churuangsuk","year":"2022","unstructured":"Churuangsuk C, Hall J, Reynolds A, Griffin SJ, Combet E, Lean MEJ. Diets for weight management in adults with type 2 diabetes: an umbrella review of published meta-analyses and systematic review of trials of diets for diabetes remission. Diabetologia. 2022;65(1):14\u201336.","journal-title":"Diabetologia"},{"issue":"10","key":"622_CR9","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.2337\/dci21-0034","volume":"44","author":"MC Riddle","year":"2021","unstructured":"Riddle MC, Cefalu WT, Evans PH, Gerstein HC, Nauck MA, Oh WK, et al. Consensus report: definition and interpretation of remission in type 2 diabetes. Diabetes Care. 2021;44(10):2438\u201344.","journal-title":"Diabetes Care"},{"key":"622_CR10","unstructured":"National Institute for Health and Care Excellence (NICE). Type 2 diabetes in adults: management. 2022. https:\/\/www.nice.org.uk\/guidance\/ng28. Accessed 10 Nov 2025."},{"issue":"2","key":"622_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004177","volume":"20","author":"R Ravindrarajah","year":"2023","unstructured":"Ravindrarajah R, Sutton M, Reeves D, Cotterill S, McManus E, Meacock R, et al. Referral to the NHS Diabetes Prevention Programme and conversion from nondiabetic hyperglycaemia to type 2 diabetes mellitus in England: a matched cohort analysis. PLoS Med. 2023;20(2):e1004177.","journal-title":"PLoS Med"},{"issue":"10","key":"622_CR12","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1007\/s00125-020-05224-2","volume":"63","author":"Y Xin","year":"2020","unstructured":"Xin Y, Davies A, Briggs A, McCombie L, Messow CM, Grieve E, et al. Type 2 diabetes remission: 2 year within-trial and lifetime-horizon cost-effectiveness of the Diabetes Remission Clinical Trial (DiRECT)\/Counterweight-Plus weight management programme. Diabetologia. 2020;63(10):2112\u201322.","journal-title":"Diabetologia"},{"issue":"3","key":"622_CR13","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S2213-8587(18)30346-2","volume":"7","author":"Y Xin","year":"2019","unstructured":"Xin Y, Davies A, McCombie L, Briggs A, Messow CM, Grieve E, et al. Within-trial cost and 1-year cost-effectiveness of the DiRECT\/Counterweight-Plus weight-management programme to achieve remission of type 2 diabetes. Lancet Diabetes Endocrinol. 2019;7(3):169\u201372.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"622_CR14","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S2213-8587(23)00385-6","volume":"12","author":"MEJ Lean","year":"2024","unstructured":"Lean MEJ, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al. 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study. Lancet Diabetes Endocrinol. 2024;12(4):233\u201346.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"622_CR15","unstructured":"NHS England. NHS Type 2 Diabetes Path to Remission Programme service specification. 2024. https:\/\/www.england.nhs.uk\/long-read\/nhs-type-2-diabetes-path-to-remission-programme-service-specification-2023\/. Accessed 10 Nov 2025."},{"issue":"9","key":"622_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14616","volume":"38","author":"N Holman","year":"2021","unstructured":"Holman N, Knighton P, Wild SH, Sattar N, Dew C, Gregg EW, et al. Cohort profile: National Diabetes Audit for England and Wales. Diabet Med. 2021;38(9):e14616.","journal-title":"Diabet Med"},{"issue":"2","key":"622_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/obr.12961","volume":"21","author":"RM Mackenzie","year":"2020","unstructured":"Mackenzie RM, Ells LJ, Simpson SA, Logue J. Core outcome set for behavioural weight management interventions for adults with overweight and obesity: standardised reporting of lifestyle weight management interventions to aid evaluation (STAR\u2010LITE). Obes Rev. 2020;21(2):e12961.","journal-title":"Obes Rev"},{"key":"622_CR18","doi-asserted-by":"crossref","unstructured":"Ells LJ BT, Matu J, Clare K, Bryant M, Burton W, Kinsella K, Evans TS, Marwood JR, Radley D, Homer C, Martin A, Tebaldi D, Zabula T, Bakhai C. Flint SW. Re:Mission Study Synopsis. A coproduced mixed method evaluation of the NHS England Low-Calorie Diet implementation pilot. 2025. https:\/\/pubmed.ncbi.nlm.nih.gov\/40751925\/. Accessed 10 Nov 2025.","DOI":"10.3310\/MPRT2139"},{"issue":"9","key":"622_CR19","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00125-013-2940-y","volume":"56","author":"AJ Hayes","year":"2013","unstructured":"Hayes AJ, Leal J, Gray AM, Holman RR, Clarke PM. UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia. 2013;56(9):1925\u201333.","journal-title":"Diabetologia"},{"issue":"10","key":"622_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14656","volume":"38","author":"J Leal","year":"2021","unstructured":"Leal J, Alva M, Gregory V, Hayes A, Mihaylova B, Gray AM, et al. Estimating risk factor progression equations for the UKPDS Outcomes Model 2 (UKPDS 90). Diabet Med. 2021;38(10):e14656.","journal-title":"Diabet Med"},{"key":"622_CR21","unstructured":"University of Oxford. UKPDS Outcomes Model Version 2.2 User Manual. 2023. https:\/\/secure.dtu.ox.ac.uk\/dl\/?File=OM2.2Manual.pdf. Accessed 10 Nov 2025."},{"key":"622_CR22","unstructured":"Leeds Beckett University. Re:Mission Study Protocol (Version 6, 31\/10\/2022) . NIHR; 2022. https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2041739. Accessed 10 Nov 2025."},{"key":"622_CR23","unstructured":"NatCen Social Research. English Longitudinal Study of Ageing (ESLA): User Guide to the Nurse Visit Datasets Waves 2,4,6,8. 2018. https:\/\/www.elsa-project.ac.uk\/. Accessed 10 Nov 2025."},{"issue":"3","key":"622_CR24","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/oby.22407","volume":"27","author":"S Kent","year":"2019","unstructured":"Kent S, Aveyard P, Astbury N, Mihaylova B, Jebb SA. Is doctor referral to a low-energy total diet replacement program cost-effective for the routine treatment of obesity? Obesity. 2019;27(3):391\u20138.","journal-title":"Obesity"},{"issue":"1","key":"622_CR25","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1177\/0272989X19889897","volume":"40","author":"S Bates","year":"2020","unstructured":"Bates S, Bayley T, Norman P, Breeze P, Brennan A. A systematic review of methods to predict weight trajectories in health economic models of behavioral weight-management programs: the potential role of psychosocial factors. Med Decis Mak. 2020;40(1):90\u2013105.","journal-title":"Med Decis Mak"},{"key":"622_CR26","unstructured":"Jones K, H. W, Birch S, Castelli A, Chalkley M, Dargan A, et al. Unit Costs of Health and Social Care 2022 Manual. Technical report. Personal Social Services Research Unit (University of Kent) and Centre for Health Economics (University of York); 2023."},{"key":"622_CR27","volume-title":"Unit costs of health and social care 2016","author":"L Curtis","year":"2016","unstructured":"Curtis L, Burns A. Unit costs of health and social care 2016. Canterbury: Personal Social Services Research Unit, University of Kent; 2016."},{"issue":"4","key":"622_CR28","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/dme.12647","volume":"32","author":"ML Alva","year":"2015","unstructured":"Alva ML, Gray A, Mihaylova B, Leal J, Holman RR. The impact of diabetes-related complications on healthcare costs: new results from the UKPDS (UKPDS 84). Diabet Med. 2015;32(4):459\u201366.","journal-title":"Diabet Med"},{"key":"622_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.p848","volume":"381","author":"J Wise","year":"2023","unstructured":"Wise J. Diabetes cases in UK reach all time high, charity warns. BMJ. 2023;381:848.","journal-title":"BMJ"},{"key":"622_CR30","unstructured":"NHS England. National Diabetes Audit (NDA) 2024-25 quarterly report for England, Integrated Care Board (ICB), Primary Care Network (PCN) and GP practice. 2025. https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/national-diabetes-audit\/core-q3-24-25\/national-diabetes-audit-nda-2024-25-quarterly-report-for-england-integrated-care-board-icb-primary-care-network-pcn-and-gp-practice. Accessed 10 Nov 2025."},{"key":"622_CR31","unstructured":"Office for National Statistics (ONS). Statistical bulletin: Population estimates for the UK, England, Wales, Scotland, and Northern Ireland: mid-2022. 2024. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/populationandmigration\/populationestimates. Accessed 10 Nov 2025."},{"key":"622_CR32","unstructured":"Public Health England. Adult obesity and type 2 diabetes. 2014. https:\/\/www.gov.uk\/government\/publications\/adult-obesity-and-type-2-diabetes. Accessed 10 Nov 2025."},{"key":"622_CR33","unstructured":"NICE. Assessing resource impact process manual. 2023. https:\/\/www.nice.org.uk\/Media\/Default\/About\/what-we-do\/Into-practice\/assessing-resource-impact-process-manual-ta-hst.pdf. Accessed 10 Nov 2025."},{"issue":"3","key":"622_CR34","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/obr.12366","volume":"17","author":"HM Parretti","year":"2016","unstructured":"Parretti HM, Jebb SA, Johns DJ, Lewis AL, Christian-Brown AM, Aveyard P. Clinical effectiveness of very-low-energy diets in the management of weight loss: a systematic review and meta-analysis of randomized controlled trials. Obes Rev. 2016;17(3):225\u201334.","journal-title":"Obes Rev"},{"issue":"9","key":"622_CR35","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(24)00194-3","volume":"12","author":"J Valabhji","year":"2024","unstructured":"Valabhji J, Gorton T, Barron E, Safazadeh S, Earnshaw F, Helm C, et al. Early findings from the NHS type 2 diabetes path to remission programme: a prospective evaluation of real-world implementation. Lancet Diabetes Endocrinol. 2024;12(9):653\u201363.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"15","key":"622_CR36","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","volume":"359","author":"RR Holman","year":"2008","unstructured":"Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577\u201389.","journal-title":"N Engl J Med"},{"issue":"1","key":"622_CR37","doi-asserted-by":"publisher","first-page":"66","DOI":"10.2337\/dc23-0781","volume":"47","author":"SL Hocking","year":"2023","unstructured":"Hocking SL, Markovic TP, Lee CMY, Picone TJ, Gudorf KE, Colagiuri S. Intensive lifestyle intervention for remission of early type 2 diabetes in primary care in Australia: DiRECT-Aus. Diabetes Care. 2023;47(1):66\u201370.","journal-title":"Diabetes Care"},{"issue":"6","key":"622_CR38","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S2213-8587(20)30117-0","volume":"8","author":"S Taheri","year":"2020","unstructured":"Taheri S, Zaghloul H, Chagoury O, Elhadad S, Ahmed SH, El Khatib N, et al. Effect of intensive lifestyle intervention on bodyweight and glycaemia in early type 2 diabetes (DIADEM-I): an open-label, parallel-group, randomised controlled trial. Lancet Diabetes Endocrinol. 2020;8(6):477\u201389.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"622_CR39","volume":"19","author":"M Li","year":"2023","unstructured":"Li M, Jeeyavudeen MS, Arunagirinathan G, Pappachan J. Is type 2 diabetes mellitus a behavioural disorder? An evidence review for type 2 diabetes mellitus prevention and remission through lifestyle modification. Eur Endocrinol. 2023;19(1):7.","journal-title":"Eur Endocrinol"},{"key":"622_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2020.106100","volume":"136","author":"M Gebreslassie","year":"2020","unstructured":"Gebreslassie M, Sampaio F, Nystrand C, Ssegonja R, Feldman I. Economic evaluations of public health interventions for physical activity and healthy diet: a systematic review. Prev Med. 2020;136:106100.","journal-title":"Prev Med"},{"key":"622_CR41","doi-asserted-by":"crossref","unstructured":"GC V, Wilson EC, Suhrcke M, Hardeman W, Sutton S. Are brief interventions to increase physical activity cost-effective? A systematic review. Br J Sports Med. 2016;50(7):408\u201317.","DOI":"10.1136\/bjsports-2015-094655"},{"issue":"584","key":"622_CR42","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.3399\/bjgp11X561249","volume":"61","author":"S Garrett","year":"2011","unstructured":"Garrett S, Elley CR, Rose SB, O\u2019Dea D, Lawton BA, Dowell AC. Are physical activity interventions in primary care and the community cost-effective? A systematic review of the evidence. Br J Gen Pract. 2011;61(584):e125\u201333.","journal-title":"Br J Gen Pract"},{"issue":"5","key":"622_CR43","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1017\/S0266462318000533","volume":"34","author":"J-CK Dupont","year":"2018","unstructured":"Dupont J-CK, Guillon M, Rochaix L. Cost-effectiveness of interventions based on physical activity in the treatment of chronic conditions: a systematic literature review. Int J Technol Assess Health Care. 2018;34(5):481\u201397.","journal-title":"Int J Technol Assess Health Care"},{"issue":"7","key":"622_CR44","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/dme.12711","volume":"32","author":"L Tao","year":"2015","unstructured":"Tao L, Wilson ECF, Wareham NJ, Sandb\u00e6k A, Rutten GEHM, Lauritzen T, et al. Cost-effectiveness of intensive multifactorial treatment compared with routine care for individuals with screen-detected type 2 diabetes: analysis of the ADDITION-UK cluster-randomized controlled trial. Diabet Med. 2015;32(7):907\u201319.","journal-title":"Diabet Med"},{"issue":"11","key":"622_CR45","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1111\/dom.13821","volume":"21","author":"MJ Keng","year":"2019","unstructured":"Keng MJ, Tsiachristas A, Leal J, Gray A, Mihaylova B. Impact of achieving primary care targets in type 2 diabetes on health outcomes and healthcare costs. Diabetes Obes Metab. 2019;21(11):2405\u201312.","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"622_CR46","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.2337\/dc20-0717","volume":"43","author":"J Leal","year":"2020","unstructured":"Leal J, Reed SD, Patel R, Rivero-Arias O, Li Y, Schulman KA, et al. Benchmarking the cost-effectiveness of interventions delaying diabetes: a simulation study based on NAVIGATOR data. Diabetes Care. 2020;43(10):2485\u201392.","journal-title":"Diabetes Care"},{"issue":"672","key":"622_CR47","doi-asserted-by":"publisher","first-page":"e449","DOI":"10.3399\/bjgp18X697649","volume":"68","author":"A Martin","year":"2018","unstructured":"Martin A, Saunders CL, Harte E, Griffin SJ, MacLure C, Mant J, et al. Delivery and impact of the NHS health check in the first 8 years: a systematic review. Br J Gen Pract. 2018;68(672):e449\u201359.","journal-title":"Br J Gen Pract"},{"issue":"4","key":"622_CR48","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/dme.13562","volume":"35","author":"E Barron","year":"2018","unstructured":"Barron E, Clark R, Hewings R, Smith J, Valabhji J. Progress of the healthier you: NHS diabetes prevention programme: referrals, uptake and participant characteristics. Diabet Med. 2018;35(4):513\u20138.","journal-title":"Diabet Med"},{"issue":"1","key":"622_CR49","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14689","volume":"39","author":"L Rehackova","year":"2022","unstructured":"Rehackova L, Rodrigues AM, Thom G, Brosnahan N, Barnes AC, McCombie L, et al. Participant experiences in the Diabetes REmission Clinical Trial (DiRECT). Diabet Med. 2022;39(1):e14689.","journal-title":"Diabet Med"},{"issue":"1","key":"622_CR50","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12966-014-0142-8","volume":"11","author":"A Martin","year":"2014","unstructured":"Martin A, Ogilvie D, Suhrcke M. Evaluating causal relationships between urban built environment characteristics and obesity: a methodological review of observational studies. Int J Behav Nutr Phys Act. 2014;11(1):142.","journal-title":"Int J Behav Nutr Phys Act"},{"issue":"9","key":"622_CR51","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1007\/s00125-022-05736-z","volume":"65","author":"G Li","year":"2022","unstructured":"Li G, Zhang J, Van Spall HGC, Douglas PS, Wang Y, Sun X, et al. Exploring ethnic representativeness in diabetes clinical trial enrolment from 2000 to 2020: a chronological survey. Diabetologia. 2022;65(9):1461\u201372.","journal-title":"Diabetologia"},{"issue":"7","key":"622_CR52","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.2337\/dc22-1438","volume":"46","author":"EW Gregg","year":"2023","unstructured":"Gregg EW, Patorno E, Karter AJ, Mehta R, Huang ES, White M, et al. Use of real-world data in population science to improve the prevention and care of diabetes-related outcomes. Diabetes Care. 2023;46(7):1316\u201326.","journal-title":"Diabetes Care"},{"key":"622_CR53","unstructured":"National Institute for Health and Care Excellence (NICE). NICE real-world evidence framework. 2022. https:\/\/www.nice.org.uk\/corporate\/ecd9\/chapter\/overview. Accessed 10 Nov 2025."},{"issue":"5","key":"622_CR54","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1111\/dom.14311","volume":"23","author":"E Pagano","year":"2021","unstructured":"Pagano E, Konings SRA, Di Cuonzo D, Rosato R, Bruno G, van der Heijden AA, et al. Prediction of mortality and major cardiovascular complications in type 2 diabetes: external validation of UK prospective diabetes study outcomes model version 2 in two European observational cohorts. Diabetes Obes Metab. 2021;23(5):1084\u201391.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"622_CR55","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/dom.14895","volume":"25","author":"J Hartmann-Boyce","year":"2023","unstructured":"Hartmann-Boyce J, Cobiac LJ, Theodoulou A, Oke JL, Butler AR, Scarborough P, et al. Weight regain after behavioural weight management programmes and its impact on quality of life and cost effectiveness: evidence synthesis and health economic analyses. Diabetes Obes Metab. 2023;25(2):526\u201335.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"622_CR56","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.clinthera.2020.12.015","volume":"43","author":"RE Farmer","year":"2021","unstructured":"Farmer RE, Beard I, Raza SI, Gollop ND, Patel N, Tebboth A, et al. Prescribing in type 2 diabetes patients with and without cardiovascular disease history: a\u00a0descriptive analysis in the UK CPRD. Clin Ther. 2021;43(2):320\u201335.","journal-title":"Clin Ther"},{"issue":"3","key":"622_CR57","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.jval.2021.09.005","volume":"25","author":"MJ Keng","year":"2022","unstructured":"Keng MJ, Leal J, Mafham M, Bowman L, Armitage J, Mihaylova B. Performance of the UK prospective diabetes study outcomes model 2 in a contemporary UK type 2 diabetes trial cohort. Value Health. 2022;25(3):435\u201342.","journal-title":"Value Health"},{"issue":"12","key":"622_CR58","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1038\/s41366-018-0184-0","volume":"42","author":"MA Morris","year":"2018","unstructured":"Morris MA, Wilkins E, Timmins KA, Bryant M, Birkin M, Griffiths C. Can big data solve a big problem? Reporting the obesity data landscape in line with the foresight obesity system map. Int J Obes. 2018;42(12):1963\u201376.","journal-title":"Int J Obes"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-025-00622-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-025-00622-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-025-00622-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T15:04:18Z","timestamp":1773846258000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-025-00622-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["622"],"URL":"https:\/\/doi.org\/10.1007\/s41669-025-00622-x","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"30 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors confirm that they have no conflicts of interest to declare and have received no other funding for this study. All team members have currently or recently received funding from other NIHR awards. TB has an honorary contract (unpaid) with, and received awards from, the Office for Health Improvement and Disparities (OHID). In the past she has received consultancy fees from the British Dietetic Association (2020) and the European Association for the Study of Obesity (2021). LE has held awards from OHID and Leeds City Council. She also has unpaid roles on the ACTIONTeens authorship and HOT clinical trial in Denmark.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"The Re:Mission study was approved by Health Research Authority on 5 July 2021, REC ref: 21\/WM\/0136 and Leeds Beckett University Local Research Ethics committee ref 80438.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data analysed in this study was provided to the research team for the duration of the NIHR-funded Re:Mission study by NHSE England. The authors do not have permission to share the data further or deposit in any repository.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Full details about the UKPDS-OM2 used in this study are available here:\n                      \n                      and","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conceptualization (AM, MY, LE), Methodology (AM, TZ, DT, MY, LE), Formal analysis (AM, TZ, DT, MY, LE), Investigation (AM, TZ, DT, MY, TB, LE), Data curation (AM, TZ, DT, MY), Writing \u2013 original draft (AM), Writing \u2013 review & editing (AM, TZ, DT, MY, TB, LE), Visualization (AM), Supervision (AM, LE), Funding acquisition (AM, TB, LE).","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}